Mol Cancer Ther 2012, 11:2301–2305.PubMedCrossRef 32. Jang MH, Kim EJ, Choi Y, Lee HE, Kim YJ, Kim JH, Kang E, Kim SW, Kim IA, Park SY: FGFR1 is amplified during the progression Semaxanib price of in situ to invasive breast carcinoma. Breast Cancer Res 2012, 14:R115.PubMedCrossRef 33. Moelans CB, de Wegers RA,

Monsuurs HN, Maess AH, van Diest PJ: Molecular differences between ductal carcinoma in situ and adjacent invasive breast carcinoma: a multiplex ligation-dependent probe amplification study. Cell Oncol (Dordr) 2011, 34:475–482.CrossRef Competing interests The authors declare that they have no competing interests. Authors’ contribution EB drafted the manuscript, MB interpreted the molecular analyses

and drafted the manuscript, GB set up the database, AC interpreted the molecular analysis, EM participated in the sequence alignment, AN recruited tissue samples, MC recruited tissue samples, AM reviewed the criticisms, EB recruited the clinical information, FM recruited the clinical information, GT recruited the clinical information, SC recruited the clinical information, SP performed the technical experiments, MC interpreted the immunophenotypical analysis, GZ recruited tissue samples, KM verified the distribution of HER2 analysis, GM participated in the sequence alignment, FB approved, followed and managed all processing steps of research. All the authors read and approved the final manuscript.”
“Background Mizoribine datasheet Breast cancer is one of the most common malignant cancers among women worldwide. In 2012, an estimated 220,000 individuals were diagnosed with breast cancer and the mortality associated with breast cancer is nearly 40,000 in the United States [1]. Radiotherapy plays an

important role in the treatment of breast cancer. Several randomized clinical trials have shown that improved disease-free and overall survival rates were improved by the addition of radiotherapy in the treatment of women with breast cancer [2–5]. However, tumor radioresistance remains a fundamental barrier to attaining maximal efficacy with radiotherapy for the treatment of breast cancer. Radioresistance may be present at the beginning of therapy, causing the patients to fail to respond Edoxaban to treatment (intrinsic radioresistance), or it may emerge over time during radiotherapy treatment (acquired radioresistance). Fractionated radiation (FR) is often used in radiotherapy to facilitate the recovery of normal tissues. Cancer cells may acquire radioresistance during fractionated radiotherapy, which results in treatment failure. Overcoming the acquired radioresistance of breast cancer could improve the outcome of breast cancer patients who receive radiotherapy. Apoptosis, or programmed cell death, is the mechanism of radiation-induced cancer cell death [6, 7].